Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tivorsan Pharmaceuticals

Request full access

- Tivorsan Pharmaceuticals

Providence, United StatesFounded 2008Health

About Tivorsan Pharmaceuticals

Tivorsan Pharmaceuticals, established in 2007, was a biotechnology firm concentrated on creating novel protein therapeutics for severe neuromuscular disorders. The company's scientific foundation was laid by Dr. Justin Fallon of Brown University, whose 25 years of basic science work formed the basis of Tivorsan's primary therapeutic approach. Co-founder Dr. Joel B. Braunstein served as the initial CEO, steering the company through its early stages. The company was formed as a collaboration between Dr. Fallon, Old Forge Holdings, and LifeTech Research.

Tivorsan's business model revolved around the research and development of treatments for orphan diseases, specifically targeting all forms of Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). The company aimed to address these conditions by developing therapies that could be effective regardless of a patient's specific genetic mutation. Its primary focus was on advancing its lead drug candidate through the necessary preclinical and clinical trial phases to gain regulatory approval and bring a new treatment option to patients. The company secured funding through various means, including private placements, venture capital, and grants from organizations like the Muscular Dystrophy Association (MDA). Over its lifespan, the company raised approximately $13.8 million to $15.6 million.

The firm's lead product candidate was TVN-102, a recombinant human Biglycan, which is a naturally occurring protein found in muscle. The therapeutic works by up-regulating utrophin, a protein that can functionally compensate for the absence of dystrophin, the protein missing in DMD patients. This mechanism offered a promising strategy because utrophin upregulation has the potential to benefit all DMD patients. In 2016, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to TVN-102 for the treatment of DMD, a significant milestone that provides incentives for the development of drugs for rare diseases. Despite these developments and plans to initiate Phase 1 clinical trials in 2017, the company ultimately ceased operations around May 2021.

Source: Dealroom company data

Tivorsan Pharmaceuticals in the Providence ecosystem

Live from Dealroom

The Tivorsan Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • MDA
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Providence HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Tivorsan Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tivorsan Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.